Clear The Air News Tobacco Blog Rotating Header Image

Up in Smoke: Why China has Banned Foreign Investment in Tobacco

China’s Ministry of Industry and Information Technology (MIIT) recently announced regulations barring foreign investment in the country’s enormous tobacco industry, blocking foreign-invested enterprises and individual businesses from participating in tobacco wholesale, retail, and alternative forms of trading. These new restrictions come on the heels of various government efforts to reduce China’s rampant tobacco use, with middling results to date.

By Alexander Chipman Koty

China’s Ministry of Industry and Information Technology (MIIT) recently announced regulations barring foreign investment in the country’s enormous tobacco industry, blocking foreign-invested enterprises and individual businesses from participating in tobacco wholesale, retail, and alternative forms of trading. These new restrictions come on the heels of various government efforts to reduce China’s rampant tobacco use, with middling results to date.

There are more than 320 million smokers in China, making it the world’s largest producer and consumer of tobacco products. While comprising about 20 percent of the world’s population, China is responsible for 45 percent of all cigarettes consumed globally. With an ageing population, a shrinking workforce, and an increasingly prosperous society, China faces mounting pressure to look after the wellbeing of its constituents, but that comes at a significant price.

Tobacco cessation products and healthcare services stand to benefit from increased supervision of the tobacco industry. Although China is moving toward regulation, wavering government commitment because of the industry’s huge profitability and deep-seated use within society stand in the way of stamping out tobacco’s pervasive presence. The country remains a challenging market for tobacco cessation products and services.

Tobacco use in China

Tobacco use is firmly entrenched in Chinese society, with applications ranging from day-to-day use to deeper cultural practices. Usage is starkly divided between the sexes — 68 percent of Chinese men smoke, compared to only 3.2 percent of women. However, all are exposed to the negative health effects of smoking. Ineffective smoking restrictions in indoor and public places such as restaurants and offices means about 740 million Chinese are exposed to secondhand smoke. As a result of widespread tobacco use and the country’s issues with pollution, China has the most lung cancer diagnoses and fatalities in the world.

Social pressure for men to smoke is significant; those who refuse cigarettes are often met with curious looks and the offerer loses face. In China, offering cigarettes is a symbolic way of establishing trust and forming relationships, particularly among strangers. Similarly to the deep-rooted drinking culture among business people, expensive cigarettes and tobacco products are commonly presented as gifts, and there is often pressure to smoke with coworkers and business partners. Compounded with these practices are ill-informed myths and misconceptions about tobacco, including beliefs that Asians are less susceptible to tobacco’s negative health effects, that it is easy to quit, and that smoking is an ancient part of Chinese culture, according to the Lancet medical journal.

Government involvement in the tobacco industry

The Chinese tobacco market is dominated by the China National Tobacco Corporation (CNTC), a state-owned enterprise (SOE) that is responsible for 98 percent of all cigarettes sold in China. The CNTC owns more than 900 brands, from large ones such as Hong Shuangxi, Yun Yan, and Zhongnanhai, to smaller regional brands and derivatives. The CNTC’s state monopoly has made the penetration of foreign brands largely unsuccessful, and only a small number of them have been manufactured in China. Foreign companies are only able to manufacture and sell their tobacco products through a joint venture with the CTNC. For example, Marlboro, one of the world’s largest tobacco brands, only started manufacturing in China in 2008 after coming to an agreement with the CNTC to promote Chinese brands overseas.

Government restriction of foreign competition is largely explained by tobacco’s extraordinary profitability. Further, restricting foreign companies’ access to China increases the CNTC’s leverage to access international markets and compete with established brands. An incredible 7-10 percent of all government revenue is through tobacco sales, giving the State Tobacco Monopoly Administration (STMA) vast power. Chinese Premier Li Keqiang’s younger brother headed the STMA until February 2015, demonstrating its stature. While the long-term costs of medical services and premature losses of workers is higher than immediate profits, it is difficult for the government to jettison a steady source of revenue by committing to tobacco dissuasion at a time when other streams are slowing.

The uneven implementation of recent reforms points to this reluctance. The government issued a draft law for public consultation in late 2014 banning smoking in all indoor places and some outdoor ones, as well as restricting advertising, and in 2015 raised taxes on wholesale cigarettes from 5 to 11 percent. However, the government ultimately backtracked on many of its initial proposals, allowing restaurants, bars, hotels, and airports to have smoking sections and allowing smoking in individual offices. Combined with infrequent enforcement of existing restrictions, the laws do little to dissuade smoking.

The tobacco cessation market

Government efforts to discourage smoking, however halfhearted, combined with China’s massive smoking population offer immense but difficult-to-grasp potential for tobacco cessation products.

Tobacco cessation products encounter a variety of challenges when attempting to penetrate the Chinese market. Nicotine patches are the most popular cessation product in China; other products with varying degrees of scientific credibility that are also used include e-cigarettes, toothpaste, cigarette holders, and Chinese medicines. Product use is low. In 2014, Johnson & Johnson stopped selling its leading Nicorette product there due to poor sales. Other companies like Pfizer and Novartis have entered the Chinese market calculating a long timeframe before costs can be recovered. Despite the lack of profits, foreign pharmaceutical companies face relatively little competition, as Venturepharm is the only Chinese company producing tobacco cessation medication.

Although e-cigarettes are often marketed as an anti-smoking product, many dispute this, arguing that they are just as bad, or even worse than regular cigarettes. Regardless, there is little awareness of e-cigarettes in China, and those who use them generally do so as a fashion statement. While about 90 percent of the world’s e-cigarettes are made in the southern city of Shenzhen, almost all are exported to foreign markets. The e-cigarette industry is currently unregulated, but the National Health and Family Planning Commission has stated its intent to regulate production, sale, and use of e-cigarettes.

The disappointing performance of tobacco cessation products is in part explained by high costs. E-cigarettes in China are decidedly more expensive than regular cigarettes, and a full round of medication costs upward of RMB 2,000. The deeper cause of the tobacco cessation industry’s poor performance is the lack of awareness and desire for smokers to quit. Fewer than 25 percent of Chinese adults understand the specific health hazards of tobacco use. Additionally, fewer than 10 percent of Chinese smokers quit by choice, in comparison to more than 50 percent in many high-income countries where there are more former smokers than smokers.


China is slowly addressing its tobacco problem. In 2015, cigarette sales in China declined for the first time in two decades, demonstrating some success in smoking dissuasion. However, this is mostly due to higher taxes curtailing frequent use, rather than reducing the number of individual smokers.

As is commonplace for foreign investors doing business in emerging economies, the specter of SOEs such as the CNTC often complicates business. Vested interests ranging from pure profits to sprawling bureaucracies and payrolls to corruption in the form of kickbacks make it difficult for foreign companies to compete with SOEs who benefit from preferential treatment. This phenomenon has tragic consequences in China’s tobacco industry, where the state’s lucrative monopoly hinders efforts to curb tobacco use, resulting in exploding cancer rates and premature deaths.

While China presents an enormous opportunity for tobacco cessation products, success will be difficult to achieve without genuine government efforts to spread awareness of tobacco’s adverse health effects. With growing healthcare costs and productivity losses, however, China is gradually moving toward tighter control of tobacco use. Although China is not yet primed for tobacco cessation products, it is a question of time before the public comes to grips with the ramifications of its smoking habit, making it essential for producers to create an entry strategy.

About the author: This article originally appeared in China Briefing, a subsidiary of Dezan Shira & Associates. Dezan Shira is a specialist foreign direct investment practice, providing corporate establishment, business advisory, tax advisory and compliance, accounting, payroll, due diligence and financial review services to multinationals investing in China, Hong Kong, India, Vietnam, Singapore and the rest of ASEAN. For further information, please or visit

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>